Compare MLCO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLCO | IOVA |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.7B |
| IPO Year | 2006 | 2008 |
| Metric | MLCO | IOVA |
|---|---|---|
| Price | $4.66 | $10.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $10.10 | $9.00 |
| AVG Volume (30 Days) | 1.6M | ★ 13.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.42 | $47.74 |
| Revenue Next Year | $4.37 | $40.31 |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.56 | $1.76 |
| 52 Week High | $9.90 | $10.98 |
| Indicator | MLCO | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 31.37 | 72.59 |
| Support Level | N/A | $3.57 |
| Resistance Level | $5.73 | N/A |
| Average True Range (ATR) | 0.17 | 0.47 |
| MACD | -0.05 | 0.06 |
| Stochastic Oscillator | 14.95 | 72.29 |
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.